Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

NCT04762030 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Durvalumab Anlotinib Carboplatin Nab-paclitaxel

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China